Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase


Autoria(s): de Faria, C. M. Q. G.; Nazare, A. C.; Petronio, M. S.; Paracatu, L. C.; Zeraik, M. L.; Regasini, L. O.; Silva, Dulce Helena Siqueira; da Fonseca, L. M.; Ximenes, V. F.
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

20/05/2014

20/05/2014

01/10/2012

Resumo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

This study presents the increased efficiency of NADPH oxidase inhibition produced by esterification of protocatechuic acid (P0). Alkyl esters bearing chain lengths of 4 (P4), 7 (P7) and 10 (P10) carbons were synthesized and their oxidation potential, hydrophobicity, antiradical activity, inhibition of superoxide anion (O-2(center dot-)), and the abilities to affect hypochlorous acid (HOCl) production by leukocytes and inhibit myeloperoxidase (MPO) chlorinating activity were studied. The increased hydrophobicity (logP, 0.81-4.82) of the esters was not correlated with a significant alteration in their oxidation potential (0.222-0.298 V). However, except for P10, the esters were similar to 2-fold more effective than the acid precursor for the scavenging of DPPH and peroxyl radicals. The esters were strong inhibitors of O2 released by activated neutrophils (PMNs) and peripheral blood mononuclear cells (PBMCs). A correlation was found between the carbon chain length and the relative inhibitory potency. P7, the most active ester, was similar to 10-fold more efficient as NADPH oxidase inhibitor than apocynin. The esters strongly inhibited the release of HOCl by PMNs, which was a consequence of the inhibition of NADPH oxidase activity in these cells. In conclusion, as effective inhibitors of NADPH oxidase, the esters of protocatechuic acid are promising drugs for treatment of chronic inflammatory diseases. Moreover, this is the first demonstration that, besides the redox active moiety, the hydrophobicity can also be a determinant factor for the design of NADPH oxidase inhibitors.

Formato

4885-4893

Identificador

http://dx.doi.org/10.2174/092986712803341557

Current Medicinal Chemistry. Sharjah: Bentham Science Publ Ltd, v. 19, n. 28, p. 4885-4893, 2012.

0929-8673

http://hdl.handle.net/11449/8766

10.2174/092986712803341557

WOS:000309745800016

Idioma(s)

eng

Publicador

Bentham Science Publ Ltd

Relação

Current Medicinal Chemistry

Direitos

closedAccess

Tipo

info:eu-repo/semantics/review